Claims for Patent: 11,806,321

Summary for Patent: 11,806,321

Title:	Non-linear dosing of mirdametinib
Abstract:	The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Inventor(s):	Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Assignee:	SpringWorks Therapeutics Inc
Application Number:	US18/185,045
Patent Claims:	1. A method of administering mirdametinib to a human patient in need thereof comprising orally administering mirdametinib to the patient, wherein the patient suffers from a tumor or cancer, and wherein (a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily, (b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily, (c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and (d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily. 2. The method of claim 1, where the tumor or cancer is selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. 3. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein (a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily, (b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily, (c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and (d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily. 4. The method of claim 1, wherein the patient has symptomatic, inoperable plexiform neurofibromas. 5. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) that is progressing or causing significant morbidity comprising orally administering an effective amount of mirdametinib to the patient, wherein (a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily, (b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily, (c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and (d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily. 6. The method of claim 3, wherein the patient has progressive PN. 7. The method of claim 3, wherein the patient has PNs that cause significant morbidity. 8. The method of claim 3, wherein the patient has head and neck lesions that are compromising the airway or great vessels, brachial or lumbar plexus lesions that are causing nerve compression and loss of function, lesions causing major deformity or are significantly disfiguring, lesions of the extremity that cause limb hypertrophy or loss of function, or painful lesions. 9. The method of claim 8, wherein the lesions causing major deformity or are significantly disfiguring are tumors of the head and neck or those on other areas of the body that are unable to be concealed by standard garments. 10. The method of claim 3, wherein the patient has paraspinal lesions. 11. The method of claim 3, wherein the patient has the clinical diagnosis of NF1 using the NIH Consensus Conference and one or more of the following: (a) six or more café-au-lait macules with a diameter >5 mm in prepubertal and >15 mm in post-pubertal individuals; (b) freckling in axilla or inguinal regions; (c) optic glioma; (d) two or more Lisch nodules; (e) a distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia of thinning of long bone cortex); and (f) a first degree relative with NF1. 12. The method of claim 3, wherein the patient has a constitutional NF1 mutation documented in a Clinical Laboratory Improvement Amendments/College of American Pathologists certified lab. 13. The method of claim 3, wherein the patient either (a) has a parent diagnosed with NF1 and one or more criteria of (1) through (7) or (b) does not have a parent diagnosed with NF1 but has two or more criteria of (1) through (7): (1) six or more café-au-lait macules over 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in post-pubertal individuals; (2) freckling in the axillary or inguinal region; (3) two or more neurofibromas of any type or one plexiform neurofibroma (4) optic pathway glioma; (5) two or more iris Lisch nodules identified by slit lamp examination or two or more choroidal abnormalities (defined as bright, patchy nodules imaged by optical coherence tomography (OCT)/near-infrared reflectance (NIR) imaging; (6) a distinctive osseus lesion (such as sphenoid dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone); and (7) a heterozygous pathogenic NF1 variant with a variant allele fraction of 50% in apparently normal tissue such as white blood cells. 14. The method of claim 3, wherein the maximum daily dose is 4 mg mirdametinib twice daily. 15. The method of claim 3, wherein over each four week period, the mirdametinib is administered for the first three weeks and discontinued for the last one week. 16. The method of claim 3, wherein the patient has at least a 20% reduction in plexiform neurofibroma volume as determined by volumetric magnetic resonance imaging analysis following treatment with mirdametinib. 17. The method of claim 3, wherein the treatment results in decreased pain intensity. 18. The method of claim 3, wherein the treatment results in decreased pain interference. 19. The method of claim 3, wherein the dose administered is reduced due to an adverse event, wherein the dose is reduced as follows: (a) if the dose at the time of the event is 1 mg mirdametinib twice daily, then the reduced daily dose is 1 mg administered in the morning only; (b) if the dose at the time of the event is 2 mg mirdametinib twice daily, then the reduced daily dose is 2 mg administered in the morning and 1 mg administered in the afternoon or evening; (c) if the dose at the time of the event is 3 mg mirdametinib twice daily, then the reduced daily dose is 2 mg administered twice daily; and (d) if the dose at the time of the event is 4 mg mirdametinib twice daily, then the reduced daily dose is 3 mg administered twice daily. 20. The method of claim 19, wherein the adverse event resulting in the dose reduction is acneiform. 21. The method of claim 3, wherein the patient is 2 to 15 years of age. 22. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) and a body surface area of 1.05 to 1.24 m2 comprising orally administering an effective amount of mirdametinib to the patient, wherein the patient is initially administered 3 mg mirdametinib twice daily. 23. The method of claim 3, wherein the method further comprises prior to treatment (i) determining whether to select mirdametinib as a treatment for the patient, and (ii) selecting mirdametinib as a treatment for the patient at least partially based on its objective response rate, where the objective response rate is defined as at least a 20% decrease in tumor size using centrally read MRI volumetric analysis. 24. The method of claim 23, wherein in step (i), mirdametinib is selected based on a response rate of at least 70%.